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Abstract The male Otsuka Long-Evans Tokushima Fatty 
(OLETF) rat shows insulin resistance in skeletal muscle and 
visceral obesity. To obtain information on the mechanism of the 
insulin resistance in the diabetic rats, we examined the content of 
insulin-regulated glucose transporter (GLUT4) in skeletal 
muscles. The results indicate that the total content of the 
transporter is significantly decreased (P < 0.05) in muscles of the 
diabetic rats. Plasma membrane content of the GLUT4 protein 
in muscles of the diabetic rats was increased in the basal state as 
compared to control rats. Hyperinsulinemic clamps increased 
GLUT4 levels in the plasma membrane of control rats but failed 
to do so in the diabetic rats. The distribution of GLUT4 in 
OLETF rat is reminiscent of the characteristics of human non-
insulin-dependent diabetes mellitus. 
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1. Introduction 
Glucose uptake in muscle cells is considered to be mediated 
by glucose transporter proteins. Skeletal muscle expresses at 
least two glucose transporters. One is G L U T 1 , a glucose 
transporter which is mainly responsible for basal glucose up-
take, and the other is G L U T 4 , an insulin-regulated glucose 
transporter which is considered to be translocated from intra-
cellular membranes to the plasma membrane by insulin, re-
sulting in an increased muscle glucose uptake [4,5]. In human 
non-insulin-dependent diabetes mellitus ( N I D D M ) patients, 
impaired expression of G L U T 4 in skeletal muscle has not 
been observed [6-8]. Recently, it was reported that plasma 
membrane content of G L U T 4 in N I D D M patients was in-
creased in the basal state and failed to increase after euglyce-
mic hyperinsulinemic clamps [3]. 
The male Otsuka Long-Evans Tokushima Fat ty (OLETF) 
rat, which is a model of N I D D M , is an inbred strain with 
innate polyphagia, rapid body weight gain, and accumulation 
of intra-abdominal fats [1,2]. We previously examined the ex-
istence of insulin resistance in O L E T F rats by euglycemic 
hyperinsulinemic clamp experiments in vivo. In these experi-
ments, the glucose infusion rate in O L E T F rats is found to be 
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about 25-60% of that in the control strain, Long-Evans To-
kushima Otsuka (LETO) rats. Hindlimb perfusion experi-
ments showed that insulin-stimulated glucose uptake in 
O L E T F rats is 55% of that of L E T O rats, confirming skeletal 
muscle insulin resistance. However, no major defects in the 
insulin receptor functions in vitro, including insulin receptor 
binding, receptor autophosphorylat ion, and receptor tyrosine 
kinase activity, in skeletal muscle of this diabetic model were 
observed [2]. To examine whether an abnormal G L U T 4 ex-
pression and/or membrane distribution may be responsible for 
insulin resistance in skeletal muscle of O L E T F rats, we exam-
ined G L U T 4 protein levels in total and isolated plasma mem-
brane in the basal state and after a hyperinsulinemic clamp. 
G L U T 1 contents in the muscle plasma membrane of these 
rats were also examined. 
2. Materials and methods 
2.1. Materials 
Bovine serum albumin (BSA, fraction V) and phenylmethylsulfonyl 
fluoride (PMSF) were purchased from Sigma (St. Louis, MO, USA). 
An enhanced chemiluminescence (ECL) Western blotting detection 
system, peroxidase-labeled antibody, and autoradiography film (Hy-
perfilm-ECL) were obtained from Amersham Int. (Amersham, Bucks., 
UK). Anti-GLUT4 and GLUT1 antibodies were obtained from 
Eastacres (Costa Mesa, CA, USA). Antibody against Na+,K+-AT-
Pase a l subunit was obtained from UBI (Lake Placid, NY, USA). 
Other chemicals were purchased from Wako Pure Chemicals (Osaka, 
Japan). LETO and OLETF rats were raised at the Tokushima Re-
search Institute (Otsuka Pharmaceutical Co., Ltd., Tokushima, Ja-
pan). 
2.2. Membrane preparation and Western blot analysis 
Male OLETF rats and age-matched LETO rats were used in all 
experiments. Euglycemic hyperinsulinemic clamp experiments in 30-
week-old rats were performed as described previously [2]. After over-
night starvation, the animals were anesthetized with pentobarbital 
sodium (50 mg/kg body weight, i.p.). Hindlimb skeletal muscles 
were excised and immediately frozen at —80°C. The sample was pow-
dered in liquid nitrogen and was homogenized in buffer containing 10 
mmol/1 NaHCOij, 250 mmol/1 sucrose, 5 mmol/1 NaN3, and 0.1 mmol/ 
1 PMSF at 4°C as described by Klip et al. [9], with slight modifica-
tions. All subsequent steps were carried out at 4°C. Homogenates 
were centrifuged at 1200 X g for 10 min. The supernatant was retained 
and the pellet was resuspended, homogenized, and centrifuged at 
1200 Xg for 10 min. The first and second supernatants were combined 
and centrifuged at 9000 X g for 10 min. The resulting supernatant was 
again centrifuged at 227 000 X g for 75 min to produce total crude 
membranes, and the pellet was resuspended in the buffer. The plasma 
membrane fraction was isolated by the method of Galante et al. [10]. 
Briefly, approximately 3 g of tissue was powdered and homogenized 
in 0.2 mol/1 Tris-HCl, 1 mmol/1 EDTA, 255 mmol/1 sucrose, 0.5 mg/ml 
bacitracin, 1 mmol/1 PMSF, 0.2 mg/ml benzamidine, 100 mmol/1 so-
dium fluoride, 10 mmol/1 sodium pyrophosphate, and 1 mmol/1 ortho-
vanadate (pH 7.4). Homogenate was centrifuged at 8700 X g for 20 
min. The pellet was resuspended in buffer as described above, and 
centrifuged at 750 X g for 10 min. The resulting supernatant was cen-
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trifuged again at 12000Xg for 30 min. The pellet was resuspended in 
the buffer and layered on a 38.3% sucrose cushion. After ultracentri-
fugation at 58 800 X g for 30 min, the pellet was collected at the su-
crose interface. Finally, the plasma membrane- and t-tubule-contain-
ing fraction was ultracentrifuged at 183 000 X g for 40 min. The entire 
preparation was performed on ice. Na+,K+-ATPase a l subunit was 
used as a marker of the plasma membrane fraction by immunoblot-
ting with its specific antibody. The total crude muscle membrane (100 
Hg) and the plasma membrane (10 ug) were subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
electroblotted to polyvinylidene difluoride membrane (Bio-Rad Labo-
ratories, Hercules, CA, USA) followed by treatment with rabbit anti-
GLUT4 or anti-GLUTl antibody (1:500) and a secondary peroxi-
dase-labeled antibody (1:1000). Protein concentration was determined 
by the Lowry method using BSA as a standard [11]. The glucose 
transporter protein was detected using a non-radioisotopic ECL meth-
od as a fluorogram on autoradiography film, and the density of the 
band at the glucose transporter position was measured using an Ul-
troscan XL, Enhanced Laser Densitometer (LKB, Bromma, Sweden). 
Membrane to membrane normalization was performed by the appli-
cation of same sample. 
2.3. Blood analysis 
Serum glucose, serum cholesterol, serum NEFA (Wako Pure Chem-
icals, Osaka, Japan) and serum triglycéride (Ono, Osaka, Japan) were 
analyzed using commercial kits. Serum insulin was determined by 
radioimmunoassay (Amersham). 
2.4. Statistical analysis 
All values are expressed as the mean ± S.E.M. Statistical signifi-
cance was examined by two way analysis of variance followed by 
two-tailed /-test at each week of age. P values of less than 0.05 
were considered to be significant. 
3. Results 
3.1. Characteristics of the animals 
The body weight, fasting serum glucose, serum triglycéride, 
serum cholesterol, serum N E F A , and serum insulin of the 
L E T O and O L E T F rats used for these experiments are shown 
in Table 1. Body weights of O L E T F rats were significantly 
higher than those of LETO rats at 6 (P < 0.001) and 30 
D LETO 
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Fig. 1. Western blot analysis of GLUT4 in skeletal muscle of 
LETO and OLETF rats. The muscle membranes (100 ug of protein) 
from 6- and 30-week-old LETO and OLETF rats were applied to 
SDS-PAGE and electroblotted to polyvinylidene difluoride mem-
brane followed by treatment with anti-GLUT4 antibody and a sec-
ond peroxidase-labeled antibody as described in Section 2. The 
GLUT4 protein was detected using an ECL method as a fluoro-
gram on autoradiography film. Densitometric values for protein lev-
el of GLUT4 from skeletal muscle of 6- and 30-week-old LETO 
and OLETF rats are shown. Results are means ± S.E.M., *P<0.05 
vs. age-matched LETO rats (n = 5). 
Basal Clamp 
Fig. 2. Plasma membrane content of GLUT4 proteins in hindlimb 
muscle of LETO and OLETF rats before (Basal) and after the eu-
glycemic hyperinsulinemic clamp (Clamp) experiments. Na+ ,K+-AT-
Pase a l subunit was used as marker protein in plasma membrane 
of skeletal muscle in these rats. The Na+,K+-ATPase a l subunit 
and the GLUT4 proteins were detected using an ECL method as a 
fluorogram on autoradiography film before and after the clamp ex-
periment. Densitometric values for protein level of GLUT4 from 
skeletal muscle of 30-week-old LETO and OLETF rats are shown. 
Results are means ± S.E.M., *P<0.05 (n = 5). 
( P < 0 . 0 1 ) weeks of age. Serum triglycéride of O L E T F rats 
significantly increased 3.7- and 8.4-fold at 6 (P< 0.001) and 
30 ( .P<0.01) weeks of age, respectively. Serum cholesterol 
was higher in O L E T F rats than in L E T O rats at 30 weeks 
of age (P < 0.05). Serum N E F A was significantly increased in 
O L E T F rats at 30 (P < 0.05) weeks of age. Serum insulin was 
higher in O L E T F rats at 30 weeks of age (P < 0.05). 
3.2. Euglycemic hyperinsulinemic clamp experiments 
Blood glucose concentrations during the clamp experiments 
were 4.92 ± 0.02 and 5.47 ± 0.02 mmol/1 (not significantly dif-
ferent), and the glucose infusion rate values were 12.2 ±1 .6 
Clamp 
Fig. 3. Plasma membrane content of GLUT1 proteins in hindlimb 
muscle of LETO and OLETF rats before (Basal) and after the eu-
glycemic hyperinsulinemic clamp (Clamp) experiments. Densitomet-
ric values for protein level of GLUT1 from skeletal muscle of 30-
week-old LETO and OLETF rats are shown as described in Fig. 2 
legend. Results are means ± S.E.M., **P<0.01 (rc = 5). 
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Table 1 
Characteristics of the Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans Tokushima Fatty (OLETF) rats 
Age (weeks) 
Body weight (g) 
Fasting serum glucose (mmol/1) 
Fasting serum triglycéride (mmol/1) 
Fasting serum cholesterol (mmol/1) 
Fasting serum NEFA (umol/1) 
Fasting serum insulin (ng/1) 
Means±S.E.M. *P<0.05, **P<0.01, ***P<0.001 vs. age-matched LETO rats (n = 5). 
6 weeks 
LETO 
145 ±4 
4.71 ±0.33 
0.466 ±0.060 
2.40 ±0.04 
614 ±50 
0.539 ±0.047 
OLETF 
196 ±8*** 
4.55 ±0.16 
1.72 ±0.09*** 
2.28 ±0.10 
821 ±116 
0.562 ±0.034 
30 weeks 
LETO 
507 ±4 
6.71 ±0.44 
0.376 ±0.053 
2.47 ±0.04 
602 ± 56 
1.84 ±0.33 
OLETF 
638 ±18** 
7.99 ±0.55 
3.15 ±0.40** 
3.98 ±0.39* 
873 ±70* 
4.54 ±0.78* 
and 3.08 ±1.33 mg-min^-kg -1 (P<0.01) in LETO and 
OLETF rats, respectively. Insulin concentrations after the 
clamp experiments were 10.811.9 in control and 16.3 ±1.7 
ug/1 in the diabetic rats (not significant). 
3.3. Western blot analysis of GLUT4 
To study the mechanism of insulin resistance of OLETF 
rats, Western blot analysis of GLUT4 protein level in skeletal 
muscle was carried out at 6 and 30 weeks of age (the predia-
betic and diabetic stages, respectively). When compared with 
the control strain, GLUT4 protein level in OLETF rats 
showed no significant differences at 6 weeks and was signifi-
cantly lower (P<0.05) at 30 weeks of age (Fig. 1). The 
Na+,K+-ATPase oil contents were not different in these rats 
(data not shown). We next investigated the plasma membrane 
content of GLUT4 protein in these rats. The experiments 
showed that the muscle GLUT4 protein content was increased 
by 49% in the diabetic rats in the basal state. Furthermore, 
hyperinsulinemia increased plasma membrane GLUT4 con-
tent significantly in the control rats but not in diabetic muscle 
(Fig. 2). 
3.4. Western blot analysis of GLUT1 
GLUT1 protein content in plasma membrane of skeletal 
muscle was not different in these two types of rats in either 
the basal or the insulin-stimulated state (Fig. 3). Interestingly, 
GLUT1 protein levels in plasma membranes of skeletal 
muscle of these rats were decreased after the clamp states. 
4. Discussion 
GLUT4 protein level in total membrane content in 30-
week-old OLETF rat was decreased significantly compared 
to LETO rats (Fig. 1). The GLUT4 levels in skeletal muscle 
of other animal models were the same as or lower than in 
controls. In diabetic Zucker fa/fa and viable yellow mice, 
the GLUT4 levels in skeletal muscle were decreased [12]. In 
db/db mice, no differences were observed compared to lean 
mice [13]. From these studies and the results in humans [6-8], 
it has not been confirmed that the total contents of GLUT4 
protein reflect the decrease of insulin-stimulated glucose up-
take in skeletal muscle, indicating that investigations of the 
translocation and activity of the GLUT4 protein will be im-
portant. However, there were only few studies where trans-
location of the GLUT4 protein was examined possibly mainly 
because of the difficulty of fractionating skeletal muscle mem-
branes. King et al. [14] reported a defect in GLUT4 trans-
location in muscle of Zucker rats. However, Galante et al. [10] 
found that there were no differences in GLUT4 translocation 
in muscles of lean and obese rats. The discrepancy may have 
resulted from differences in the methods of fractionation. Re-
cently, it was shown that in NIDDM patients, the plasma 
membrane content of GLUT4 was higher than in controls 
and no increase was observed after insulin infusion [3]. These 
findings are similar to our results in muscles of OLETF rats 
(Fig. 2). Na+,K+-ATPase od subunit protein is a housekeep-
ing protein of plasma membranes, and therefore we used this 
protein as internal standard to quantify GLUT4 protein con-
tent in this fraction. After euglycemic hyperinsulinemic 
clamps, GLUT4 content in the plasma membrane fraction 
was increased significantly in the LETO rats, but not signifi-
cantly in the diabetic rats. STZ-induced hyperglycémie rats 
[15] and the hyperglycémie hyperinsulinemic obese model 
[16] showed GLUT1 contents in plasma membranes were 
higher than those of controls. The GLUT1 content was also 
increased in OLETF rats. Interestingly, after insulin infusion, 
the plasma membrane GLUT1 contents were decreased in 
both rats. This novel observation deserves further investiga-
tion. 
In conclusion, the redistribution of plasma membrane 
GLUT4 content in the diabetic rat is reminiscent of that of 
human NIDDM. The OLETF rat is a very useful model for 
the elucidation of insulin resistance in NIDDM patients. 
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